PhRMA

The Other Side of Opioid Limits
The Other Side of Opioid LimitsProponents argue that limits reduce the risk of addiction, but are they keeping pharmacists from caring for their patients?
Are Rebates Responsible for Higher Drug Costs?A new study shows how the Medicare donut hole could be costing patients.
Drug chains, ASHP Support Anti-Price Gouging Campaign
Drug chains, ASHP Support Anti-Price Gouging CampaignA new campaign takes aim at drug prices, but is it the right approach?
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
How Vermont aims to cut drug spendingIf a proposed Vermont bill is successful, drug companies would have to explain why they hiked prices on certain drugs.
Pharma responds to critics with new drug adsPhRMA ad campaign features new patient and researcher stories.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
Oncology drugs in the pipelineSeveral new drugs hold promise, but cost is a top concern.
Be vigilant of counterfeit version of Botox found in United StatesA counterfeit version of onabotulinumtoxinA (Botox) was found in the United States and may have been sold to doctors’ offices and medical clinics nationwide. The version is considered unsafe and should not be used.
340B drug program causing controversyControversy surrounds the 340B Drug Discount Program, and many industry leaders agree that the healthcare law plays a large part.